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Abstract
 The innate immune response is a tightly regulated processBackground:
that reacts rapidly in response to pathogen-associated molecular patterns
(PAMPs) such as lipopolysaccharide (LPS). Evidence is accumulating that
microRNAs contribute to this, although few studies have examined the early
events that constitute the “primary” response.
 LPS-dependent changes to miRNA expression were studied inMethods:
primary human monocyte-derived macrophages (1°MDMs). An unbiased
screen by microarray was validated by qPCR and a method for the absolute
quantitation of miRNAs was also developed, utilising 5’ phosphorylated
RNA oligonucleotide templates. RNA immunoprecipitation was performed
to explore incorporation of miRNAs into the RNA-induced silencing
complex (RISC). The effect of miRNA functional inhibition on TNF
expression (mRNA and secretion) was investigated.
 Of the 197 miRNAs expressed in 1°MDMs, only five were inducedResults:
>1.5-fold. The most strongly induced was miR-155-3p, the partner strand to
miR-155-5p, which are both derived from the MIR155HG/BIC gene
(pri-miR-155). The abundance of miR-155-3p was induced transiently
~250-fold at 2-4hrs and then returned towards baseline, mirroring
pri-miR-155. Other PAMPs, IL-1β, and TNF caused similar responses.
IL-10, NF-κB, and JNK inhibition reduced these responses,
unlike cytokine-suppressing mycolactone. Absolute quantitation revealed
that miRNA abundance varies widely from donor-to-donor, and showed that
miR-155-3p abundance is substantially less than miR-155-5p in
unstimulated cells. However, at its peak there were 446-1,113 copies/cell,
and miR-155-3p was incorporated into the RISC with an efficiency similar to
miR-16-5p and miR-155-5p. Inhibition of neither miRNA affected TNF
secretion after 2hrs in 1°MDMs, but technical challenges here are noted.
 Dynamic regulation of miRNAs during the primary responseConclusions:
is rare, with the exception of miR-155-3p. Further work is required to
establish whether its low abundance, even at the transient peak, is
sufficient for biological activity and to determine whether there are specific
mechanisms determining its biogenesis from miR-155 precursors
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            Amendments from Version 1
The abstract conclusion has been edited carefully to emphasise 
limitations of the study.
Some small changes to the introduction in response to reviewer 
comments, such as the use of formal gene names are given 
where the common name is different, the difference between 
primary and secondary responses in TLR-activated myeloid cells 
and justification of the experimental model chosen. It also rewords 
various sentences to avoid potentially confusing interpretations. 
Another publication that showed induction of miR-155-3p 
during hypoxic response of glioblastoma cells is included in the 
introduction and discussion.
The term “pri-miR-155” is now used instead of “BIC” as it more 
accurately reflects that a precursor is being quantified. Figure 2, 
Figure 3 and Figure 6 have been amended to contain the relevant 
label changes.
There are two new data figures. Figure 1D is additional validation 
data on an unchanged miRNA from the microarray data set. 
Figure 1H is Gene Ontology analysis of predicted targets of miR-
155-5p and miR-155-3p. Table 3 now includes the 2hrs LPS data 
for all three miRNAs.
The discussion has been substantially remodelled to improve 
clarity with some paragraphs moved to improve flow. A detailed 
discussion of targets of both miR-155-5p and miR-155-3p and 
the Gene Ontology analysis is now included. In addition, the 
paragraphs describing the role for KHSRP in defining which 
isoform is found in cells, and one discussing the threshold for 
biological activity, have been rewritten. A paragraph on the 
potential changes to half-lives of miRNAs has been added. The 
concluding final paragraph discussing the limitations of the study.
Eleven references have been added.
Any further responses from the reviewers can be found at the 
end of the article
REVISED
Introduction
In recent years, microRNAs have emerged as important post-
transcriptional regulators of gene expression1. They are mostly 
produced first as primary transcripts (pri-miRNAs; usually 
from pol II-dependent promoters) that are subsequently proc-
essed by DROSHA/DGCR8 in the microprocessor to form ~70nt 
hairpin structures (pre-miRNAs) that have the potential to encode 
two different miRNAs. The pre-miRNAs are exported from the 
nucleus, processed further by DICER into mature miRNAs and 
loaded into the RNA-induced silencing complex (RISC) to carry 
out their regulatory functions. The fine detail of this canonical 
pathway of miRNA biogenesis and other non-canonical path-
ways have been extensively reviewed elsewhere1–3 The two 
miRNAs that can be encoded on a pre-miRNA have historically 
been known as the ‘guide’ and ‘passenger’ strands, with the lat-
ter being referred to as the “star” miRNA. Early on, these were 
thought to be degraded with only the ‘guide’ strand going on to 
perform gene regulatory functions4. An increasing body of evidence 
has revealed this not to be the case, and in miRbase, the public 
repository for miRNA sequence annotation, the two strands are 
now referred to as -5p and -3p, indicating whether the miRNA is 
located at the 5’ or 3’ end of the pre-miRNA5. This recognises that 
each form has the potential to play a regulatory role depending 
on its expression in different cells, or in response to stimuli.
Inflammation is one of the most rapid and tightly regulated proc-
esses of the immune response, and includes the activation of cells 
by pathogen- and damage-associate molecular patterns (PAMPs 
and DAMPs) that are recognised by pattern recognition recep-
tors (PRRs) including the Toll-like receptors (TLRs)6. For exam-
ple, lipopolysaccharide (LPS) is recognised by a complex of 
TLR4 with CD14 antigen and MD2/LY96 (Myeloid Differentia-
tion Protein-2/Lymphocyte Antigen 96). Following activation, at 
least two well-defined signalling pathways are activated, includ-
ing MyD88-IRAK-4-TRAF6-NFκB and TRIF-TRAF3-IRF3. 
Many cell types can respond to PAMPs and DAMPs however, 
inflammation in the innate immune response is primarily mediated 
by monocytes and macrophages of the myeloid lineage, in par-
ticular by production of the alarm cytokine TNF. It is well- 
established that the response can be divided into two phases. A 
primary response, which does not require new protein synthesis, 
and a secondary response that does. For instance, many of the 
cytokines secreted during the primary response can stimulate 
cytokine receptors by autocrine/paracrine mechanisms further 
stimulating the cells.
Several microRNAs are commonly found to be upregulated dur-
ing disease states involving inflammation7, and at least two of 
these (miR-155-5p and miR-146a-5p) are regulated by NFκB, 
downstream of TLR signalling. Indeed, miR-155 is one of the 
most intensively studied immune microRNAs8. This well con-
served miRNA is encoded by the MIR155HG gene, previously 
known as non-coding B cell integration cluster (BIC), which has 
three exons (in humans) the third of which contains the miR-155 
pre-miRNA. Overexpression of MIR155HG causes spontaneous 
lymphoma in mice9. On the other hand, MIR155HG knockout 
causes defects in germ centre formation and Ig class switching, 
leading to immunodeficiency10. The function of miR-155 as a 
master switch in inflammation has been extensively reviewed 
elsewhere7,8. Briefly, induction of miR-155-5p by inflammatory 
stimuli including LPS in myeloid cells (monocytes, macrophages 
and dendritic cells), B and T cells has been widely reported.
The existence and function of the -3p miRNA for miR-155 has 
been less intensively studied and is more controversial. While 
miR-155-3p has been present in miRbase for many years (origi-
nally annotated as miR-155*), it was Zhou et al. who first 
described TLR7-dependent induction of both miR-155-5p and 
miR-155-3p in plasmacytoid dendritic cells11. It has since 
been shown to be induced by cytokines (TNF and IL-1β/IFNγ) 
and TLR3 ligands in astrocytes12, during LPS stimulation of tro-
phoblasts13, and during Mycobacterium tuberculosis infection 
of monocyte-derived DCs14. In murine systems, miR-155-3p 
has been shown to be upregulated in M1 (LPS and IFNγ) bone 
marrow-derived macrophages15, as well as in infiltrating T helper 
cells in experimental autoimmune encephalomyelitis16. As well 
as immune pathways, miR-155-3p has been reported to be regu-
lated in other physiological process, including downregulation 
during cardiogenesis from embryonic stem cells17 and in human 
glioblastoma cells during hypoxia18. It was also identified in a 
methylated form in mantle cell lymphoma (MCL; an aggres-
sive B-cell non-Hodgkin’s lymphoma), and demethylation 
resulted in increased expression, revealing tumour suppressing 
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properties19. Despite this, the TargetScan database20 includes 
miR-155-3p as a “not confidently identified miRNA”. Here, an 
arbitrary cut-off of ~1,000 copies/cell of an miRNA is defined 
as that minimum required for biological function, although no 
mechanistic data is provided in support of this.
Most of the studies mentioned above, similar to the miRNA 
field more widely, utilise relative expression of miRNAs using a 
range of techniques such as q-RTPCR, miRNAseq and/or micro-
arrays that result in finding of fold-changes under different con-
ditions. While such analyses are highly informative, most do not 
provide information on the abundance of the miRNAs, itself 
known to vary widely. One way of deriving this information is 
to perform absolute quantitation of the miRNAs (AQ-miRNA) 
by PCR; however, there is a lack of specific published protocols 
describing the methodology. Here, a widely applicable method 
using 5’ phosphorylated RNA oligonucleotides as the template 
in two-step miRNA expression assays is described.
This manuscript reports some historical data, in which a miRNA 
microarray was performed to investigate changes to miRNA 
abundance during the primary immune response. The ration-
ale was that since cytokines are produced by myeloid cells in an 
inflammatory “burst” with signalling events and key transcripts 
being increased transiently, any miRNA involvement in this 
pathway would also need to be rapid, within minutes/hours of 
TLR activation. Hence, the model chosen was primary human 
monocyte-derived macrophages (1°MDM) stimulated with LPS 
to specifically examine TLR signalling pathway activation 
rather than macrophage polarisation. This revealed the transient 
upregulation of miR-155-3p during the early stages of the innate 
immune response. Abundance of miR-155-3p was around 10-fold 
lower than miR-155-5p but at its peak it was shown to be incor-
porated into the RISC. It remains unclear whether miR-155-3p 
has biological function because of its low abundance and lack 
of functional data obtained. In contrast to previous studies21,22, 
here neither miR-155-5p nor miR-155-3p could be shown to 
influence TNF secretion by 1°MDM. This might be explained by 
the fact that most other studies looked at longer-term responses, 
rather than the primary response as was the focus here.
Methods
Reagents
RPMI 1640 cell culture medium and FBS were from PAA. TLR-
grade LPS from Escherichia coli was from Sigma Aldrich. Other 
TLR ligands were: poly(:IC), MALP-2, Flagellin and R848 
(all from Alexis Biochemicals), and Pam3Cys-Ser(Lys)4.3HCl 
(Pam3Cys) from Invivogen. Cytokines (M-CSF, GM-CSF, IL-1β, 
IL-10 and TNF) were from Peprotech. The inhibitors SB203580, 
PD98059 and SP600125 were from Calbiochem. Cyclohex-
imide (CHX) was from Sigma Aldrich. Mycolactone A/B 
purified from Mycobacterium ulcerans was a gift from Prof 
Pamela Small (University of Tenessee). Synthetic mycolactone 
A/B was a gift from Prof Yoshito Kishi (Harvard University). All 
reagents were tested for contamination with endotoxin using 
the limulus amebocyte lysate assay (Lonza) and found to have 
<0.1 U/ml LPS.
Primary human monocyte-derived macrophages, cell 
culture, RNA extraction, gene expression assays
Primary human monocytes were obtained from plateletphoresis 
residues purchased from the North London Blood Transfusion 
Service. Mononuclear cells were routinely isolated by Ficoll-
Hypaque centrifugation followed by elutriation as previously 
described23,24. Monocyte-derived macrophages (MDMs) were 
obtained by differentiating the cells for 4 days with 10 ng/ml 
M-CSF in complete RPMI with 10% FCS but lacking antibiot-
ics. The data in this manuscript was derived from at least 10 
independent enrichments and differentiations.
1°MDMs were harvested then re-plated at 1x106 cells/ml and 
were routinely stimulated with 100 ng/ml LPS. Other TLR ligands 
were used at different concentrations: poly(:IC); 20 µg/ml, 
Pam3Cys; 10 ng/ml, MALP-2; 30 ng/ml, Flagellin; 10 ng/ml 
and R848; 1 µg/ml. All cytokines were used at 10 ng/ml. When 
used, the final concentration of other inhibitors were SB203580 
(p38; 1 µM), PD98059 (ERK, 20 µM), SP600125 (JNK, 10 µM), 
CHX (translation, 10 µg/ml), and PSI (proteasome inhibitor/ 
NFκB, 5 µM) were pre-incubated with the cells for 1 hr prior to 
stimulation. Mycolactone A/B was used a different concentra-
tions depending on its provenance, and at concentrations shown 
to completely inhibit TNF secretion23,25; 10ng/ml for natural 
mycolactone A/B and 200ng/ml for synthetic mycolactone.
Samples were harvested by washing twice with sterile PBS and 
the addition of 600 µl miRvana Lysis/homogenisation buffer 
(Ambion/Life technologies). Total RNA was extracted using the 
miRvana miRNA purification kits (Ambion/Life Technolo-
gies) according to the manufacturer’s instructions. Quantitation 
and QC was by nanodrop. Samples were routinely investigated 
for the abundance of TNF mRNA and cytokine secretion (by 
in-house ELISA23,24), as an external control for expected behaviour 
of the cells in response to ligands and/or inhibitors. Changes in 
steady-state gene expression were assessed in one-step RT-PCR 
reactions using RNA-to-Ct reagents and Taqman gene expres-
sion probes (both Applied Biosystems) using the following 
probes: TNF; Hs00174128_m1, pri-miR-155; Hs01374569_m1, 
GAPDH, #4352934-1101034. Cycling conditions were 50°C for 
15 minutes, 95°C for 2 minutes then 40 cycles of 95°C for 
15 seconds and 58°C for 25 seconds on an ABI 7900HT instru-
ment (Applied Biosystems) in either duplicate or triplicate with 
a 384-well block and reaction volumes of 6 µl.
miRNA microarray
Pooled total RNA extracted from the macrophages of four inde-
pendent human donors were used in Exiqon v10.0 dual-label 
miRcury LNA arrays, which provides 100% coverage of miRbase 
v10 (719 mature human miRNAs). RNA samples for the array 
were examined by Bioanalyser (Agilent) for quality control pur-
poses; RIN values were routinely >9. A dual-label approach was 
employed, in which each test sample was labelled with Hy3, and 
a “common reference” sample (obtained by combining equal 
quantities of RNA from each of the six experimental data 
points) was labelled with Hy5. This approach ensured that 
all possible miRNAs produced at any experimental condition 
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should be present in the common reference pool. This was con-
sidered vital in the experimental design, as many miRNAs were 
expected to be induced by LPS. The microarray was performed 
by Exiqon as a contracted service. Background subtraction used 
a convolution model; Normexp with offset value 126. Normalisa-
tion was by LOWESS regression. Spots where no signal above 
background was detected were removed.
Gene ontology for the predicted targets of miR-155-5p and 
miR-155-3p was performed using predicted targets obtained from 
miRDB27 and Panther version 14.1 over-representation test28. 
The references was Homo sapiens (all genes) and Panther path-
ways were examined using Fisher’s exact test. All significantly 
over-represented pathways in the predicted target list are shown.
Method for the absolute quantitation of miRNAs
Relative changes in miRNA abundance were quantified using 
Taqman miRNA assays (Applied Biosystems) using the follow-
ing probes: hsa-miR-155; #2623, hsa-miR-155#; #2287, hsa-
miR-16; #39. These include a miRNA reverse transcription step 
to create a miRNA-specific cDNA that also introduces extension 
sequences that can be used as the template for qPCR in the sec-
ond step using the TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems). The manufacturer’s recommendations 
were followed, with 80 ng total RNA as the input. After reverse 
transcription, 50 µl nuclease water was added, diluting the reac-
tions by 4.3-fold. Subsequent qPCR was performed using an 
ABI 7900HT instrument in either duplicate or triplicate with 
a 384-well block and reaction volumes of 10 µl. Each reac-
tion consisted of 4.5 µl of the diluted reverse-transcription reac-
tion, 5 µl of 2x Universal PCR Master Mix, No AmpErase UNG 
(Applied Biosystems), 0.35 µl of the specific 20x Taqman Assay 
and 0.15 µl nuclease-free water. Singleplex reactions were used 
because multiplex reactions were found to significantly alter 
the ΔCts during the highly dynamic TLR4 response (for example 
see raw data file 5_171, available on OSF29). Negative controls 
included separate NTCs for reverse transcription and PCR 
steps. Cycling conditions were 95°C for 10 minutes then 
40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
All PCR-based absolute quantification (AQ) approaches involve 
the amplification of templates at known concentrations in 
order to form a standard curve based on Ct values. Hence, the 
AQ-miRNA approach uses synthetic miRNAs (5’ phosphor-
ylated RNA oligonucleotides, Eurofins MWG) as the template 
for miRNA reverse transcription reactions (see Results). These 
corresponded to the miRbase sequences of hsa-miR-16-5p, 
hsa-miR-155-5p and has-miR-155-3p (Table 1). The oligo-
nucleotides were re-suspended in nuclease-free water at a 
concentration of 100 pmol/µl (100 pM) and stored at -80°C.
To generate the standard curve, serial dilutions of the syn-
thetic miRNAs were reverse transcribed using the correspond-
ing RT Primer and an input range 0.001–100 fmol/reaction 
(in 5 µl, giving a total volume of 15 µl). This was achieved by 
diluting each synthetic miRNA to 20 fmol/µl (0.2 µM) then per-
forming eight 1 in 10 dilutions in nuclease-free water. Due 
to the extremely low concentration of miRNAs resulting, the 
dilutions were made from stocks fresh each occasion. No other 
alterations were made to the manufacturer’s protocol and 
test samples were reverse transcribed in parallel with the stand-
ard curve. These were either 80 ng total RNA, or 5 µl of the 
total RNA obtained during RIP (equivalent to 6.25% of the total, 
see below). Subsequently all standards and test samples were 
handled in an identical manner, and absolute quantitation was 
performed on the ABI 7900HT with the same reaction set 
up as described above.
This analysis gave results with the units “fmol”. For analy-
sis of cellular abundance of a particular miRNA, this equated to 
fmol/80 ng total RNA. In order to convert this value into 
copies/cell, the following calculation was performed: 
= × × ÷86.02 10 .
80
copies total average yield RNAngfmol in qPCR x no of cells
cell ng
RNA immunoprecipitation (RIP) of miRNAs loaded in the 
RISC
In order to determine whether miRNAs were incorporated into 
the RISC complex following their expression, an RNA immu-
noprecipitation (RIP) strategy was employed, building on 
the method of Wang30. Here, approximately 10x106 MDMs 
were treated, then washed twice on ice with ice-cold PBS then 
lysed with Ago lysis buffer (ALB) for 10 mins on ice, then 
centrifuged for 10 mins at 4°C. ALB contained 20 mM Tris 
(pH 7.5) 200 mM NaCl, 2.5 mM MgCl2, 0.5% Triton X-100, 
1x protease inhibitor cocktail (Sigma) and 100 U/ml RNasin 
(Promega) made up in RNase free water.
The supernatant-containing the cytoplasmic fraction was 
pre-cleared with protein G sepharose beads [pre-treated with 
0.5 mg/ml tRNA (Invitrogen) and 1 mg/ml BSA (New Eng-
land Biolabs) to block non-specific binding sites] for >30 mins. 
Beads were removed by centrifugation and the supernatant was 
processed for RIP.
For RIP, precoated Protein G sepharose beads were prepared by 
incubation with either 2 µl of ascities fluid containing antibod-
ies to human Argonaute proteins (2A8, kind gift of Zissimos 
Mourelatos, University of Pennsylvania)31 or normal mouse 
serum (as a control, containing non-relevant IgGs), then blocked 
with 0.5 mg/ml tRNA and 1 mg/ml BSA, as above. Precoated 
beads were then incubated with the precleared supernatants for 
at least 1.5 hours. Beads were then washed twice with ice cold 
ALB, then three times with high salt/detergent ALB (ALB 
containing 900 mM NaCl and 1% Triton-X-100), then twice 
Table 1. Sequences of synthetic miRNAs  
(5’ phosphorylated RNA oligonucleotides).
miRNA Sequence
hsa-miR-155-5p UUAAUGCUAAUCGUGAUAGGGGU
hsa-miR-155-3p CUCCUACUAAUUAGCAUUAACA
hsa-miR-16-5p UAGCAGCACGUAAAUAUUGGCG
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with ALB and finally once with a low-detergent ALB (ALB 
containing 0.005% Triton-X-100). Finally, the beads were 
resuspended in 250 µl 1x DNase buffer (Promega) with 200 U/ml 
RNasin and 0.04 U/ml DNase I and incubated at 37°C for 20 mins. 
After removal of the supernatant, the beads were either boiled 
in 1x Gel Sample Buffer for SDS-PAGE and immunoblotting 
according to standard techniques25, or they were resuspended in 
600 µl miRvana Lysis/homogenisation buffer for RNA extrac-
tion. For immunoblotting, the primary antibody was 2A8 (diluted 
1 in 500), and the secondary was an HRP-conjugate polyclonal 
goat anti-mouse Ig (RRID AB_2617137) at 1 in 2000.
For miRNA AQ, the formula used to convert fmol to copies/per 
cell was: 
µ
µ
8copies 80 l
= fmol in qPCR × × 6.02×10 ÷ no.of cells
cell 5 l
Alternatively, incorporation of miRNAs is estimated as % of 
input RNA, which eliminated the need for AQ miRNA. Here, 
20% of the cell lysates were processed directly for total RNA 
before proceeding with RIP. Here, the calculation used was: 
Ct Ct (mean)–[IP – Input ] 100% input = 2 ×
20
Inhibition of miRNAs
Both miR-155-5p and miR-155-3p were inhibited using 
miRCURY LNA knockdown probes (Exiqon; miR-155-
5p, #410078-00; miR-155-3p, #410079-00; negative control 
Scramble-miR, #199002-00). Oligonucleotides were transfected 
into macrophages using Dharmafect 1 (DF1, Dharmacon) using a 
well-optimised method32. Briefly, complexes of oligonucleotides 
in a 1/50 dilution of DF1 in OmtiMEM (Life Technologies) were 
prepared. Transfections took place in serum-free RPMI with no 
phenol red to which complexes were added in a final proportion 
of 75:25%. The recovery time between transfection and stimula-
tion was 3.5 hrs. Pilot experiments showed that allowing cells to 
recover overnight (18hrs) resulted in loss of miRNA inhibition. 
After recovery, media was replaced with complete RPMI, 
then stimulated with LPS for 2 hrs.
Statistical analysis
Error calculations for technical replicates of qPCR were per-
formed using Microsoft Excel, where the errors is calculated 
from the combined standard deviation of the dCt, using the for-
mula SQRT(SUMSQ[SD of housekeeping Cts]+SUMSQ[SD 
of Gene of Interest Cts]). The minus error adds this value to the 
ddCt, calculates 2x, then calculates the difference from the final 
relative expression. This approach takes into account the 
non-linear nature of qPCR data. Excel spreadsheets showing 
this calculation are available on OSF29.
Where appropriate, data were analysed by either paired t-test 
(Figure 1, mRNA/miRNA quantification), one sample t-test on 
log2 transformed data (when compared to control with a rela-
tive expression of 1, Figure 2A, B) or ordinary one-way ANOVA 
with Bonferroni’s multiple comparison test (when compar-
ing the relative changes between pri-miR-155, miR-155-5p and 
miR-155-3p, or the abundance of mRNAs and miRNAs between 
equivalent amounts of scrambled vs miRNA specific oligonu-
cleotides). TNF production data was normalised to the control 
value (100%) then analysed by one sample t-test (Figure 2B) 
or ordinary one-way ANOVA with Bonferroni’s multiple com-
parison test (when comparing the relative secretion of TNF 
between equivalent amounts of scrambled vs miRNA specific 
oligonucleotides). All analyses were carried out using Graphpad 
Prism v7.04.
Results
Differential regulation, and differential expression of miR-
155-5p and miR-155-3p
A miRNA microarray was performed focussing on the primary 
response to LPS stimulation (TLR4 activation; 2, 4 and 8 hr) in 
primary human monocyte-derived macrophages (1°MDMs), 
and the effect of IL-10 co-incubation. The cells used in the array 
performed as expected in terms of induction of TNF mRNA 
and secretion (Figure 1A), and normalised data from the array 
appears acceptable (Figure 1B). The pooled donor approach 
used has limitations, since statistical analysis of the microarray 
data cannot be performed. Therefore, observations that are not 
supported by detailed validation should be considered cautiously. 
Of the 719 miRNAs examined, 197 were expressed in 1°MDMs 
(defined as expression greater than background in all six slides) 
and the common reference sample, representing cells in all tested 
conditions. The miRNAs exhibited a wide variation in fluorescence 
intensities in the array (see “List of miRNA expressed in primary 
human MDMs”, available on OSF29). Over the six slides, the 
variation in fluorescence intensity of the common reference was 
16±4%, suggesting good technical reproducibility. One of the 
highest expressed miRNAs was miR-16-5p, which was not altered 
upon exposure of the cells to LPS over the 8-hour time-course 
of the experiment (Figure 1C). Raw microarray data are avail-
able at the Gene Expression omnibus, accession number 
GSE125572. All other raw data are available on OSF29.
Only five miRNAs were found to be upregulated >1.5-fold at 
any time point; miR-155-5p, miR-155-3p, miR-886-5p, miR-
886-3p, and miR-147b-3p (Figure 1C and see “Microarray data 
for the 197 expressed miRNAs” available on OSF29). None were 
downregulated, neither were there any changes in response 
to 4 hrs stimulation with IL-10 alone (range 0.83–1.36-fold, 
see “Microarray data for the 197 expressed miRNAs” on OSF29). 
As time increased, more miRNAs were induced. Hence at 2 hrs, 
only miR-155-5p and miR-155-3p were upregulated >1.5 fold. 
This increased to four miRNAs (additionally miR-886-5p and 
miR-886-3p) at 4 hrs, and five (additionally miR-147b-3p) at 
8 hrs. The microarray data suggest that IL-10 may both positively 
and negatively regulate miRNA expression. Compared to 4 hrs 
with LPS alone, IL-10 increased the expression of miR-766-3p 
1.7-fold and miR-146b-3p 2.3-fold, and decreased the expres-
sion of miR-155-3p (Figure 1C, see below). Indeed, miR-155-3p 
was the most strongly upregulated miRNA at any timepoint.
Validation of the microarray data was achieved by quantify-
ing selected miRNAs by Taqman miRNA qPCR assays in four 
independent human donors. While no down-regulated miRNA 
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Figure 1. miR-155-5p and miR-155-3p are differentially regulated in primary human monocyte derived macrophages by LPS. Human 
1°MDMs were exposed to 100 ng/ml LPS and/or 10 ng/ml IL-10 for different time periods, total RNA was extracted and cell culture supernatants 
were collected. (A) Control data, showing that the cells had the expected kinetics of TNF mRNA induction and secretion in response to LPS 
and/or IL-10. N=4. Mean±SEM; paired t-test, *p<0.05. (B) Box plot showing the array data after normalisation. (C) Heat map of the miRvana 
microarray v.10 showing relative abundance of miRNAs compared to the common reference sample. Shown are the top 6 miRNAs up-
regulated by LPS at each timepoint as well as miR-146b-3p and miR-766-3p that were up-regulated by IL-10 at 4 hours, and miR-16-5p which 
did not change over the timecourse. (D, E, F) Validation of miR-146a-5p, miR-155-5p and miR-155-3p by relative expression with Taqman 
miRNA assays using RNA from 4 independent human donors. The comparator was miR-16-5p. Mean±SEM; paired t-test, *p<0.05, **P<0.01, 
ns P>0.05 (G) Panther pathways statistically over-represented within the predicted targets of miR-155-5p (701 genes) and miR-155-3p (423 
genes) in miRDB. The fold enrichment over the Homo sapiens reference dataset is displayed. (H) Relative changes to the expression of pri-
miR-155 (MIR155HG), miR-155-5p, and miR-155-3p and over time; the endogenous control for the miRNAs was miR-16-5p, for pri-miR-155 it 
was GAPDH. Mean±SEM of n=5–9 independent human donors.
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Figure 2. The effect of cell signalling inhibitors, and the M. ulcerans exotoxin mycolactone on the expression of miR-155-5p and miR-
155-3p. Human 1°MDMs were pre-incubated in the absence or presence of inhibitors/toxin for 1 hr prior to 4 hrs 100 ng/ml LPS stimulation. 
Total RNA was extracted and cell culture supernatants were collected. Relative changes to the steady state levels of pri-miR-155 (MIR155HG), 
miR-155-5p, and miR-155-3p (A, C) and TNF mRNA (B, D) were quantified; the endogenous control for the miRNAs was miR-16-5p, for pri-
miR-155 and TNF it was GAPDH. Cytokine secretion was assessed by ELISA. (A, B) The effect of different cell signalling inhibitors [SB203580 
(p38; 1 µM), PD98059 (ERK, 20 µM), SP600125 (JNK, 10 µM), CHX (inhibitor of translation, 10 µg/ml), and PSI (inhibitor of NFκB pathway, 
5 µM)]. Mean±SEM n=3–4; one sample t-test on log2 transformed data compared to ctrl (LPS stimulated cells without inhibitors) or one-way 
ANOVA. *p<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (C, D) The effect of mycolactone A/B in different forms (either purified from M. ulcerans 
bacteria “Natural MYC”, or chemically synthesised “Synthetic MYC”). Mean ± error of single donor experiments (see Methods: Statistical 
analysis).
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was identified in the array for validation, miR-146a-5p was cho-
sen as it was below the 1.5-fold threshold, despite being in the 
top 6 increased miRNAs after 4hrs LPS exposure (~1.3-fold). A 
comparable result was confirmed by PCR (Figure 3D). Both miR-
155-5p and miR-155-3p were chosen for validation of upregu-
lated miRNAs, which was successful since PCR data showed 
that miR-155-5p levels increased steadily as expected during the 
timecourse of the experiment (Figure 1E), miR-155-3p was 
>100-fold induced at 2 hours, after which the levels began to 
reduce again (Figure 1F).
Gene ontology analysis of the miRDB predicted targets of miR-
155-5p and miR-155-3p was performed using Panther over- 
representation test (Figure 1G). Both microRNAs’ predicted 
targets were over-represented in genes that participate in the 
gonadotropin-releasing hormone receptor pathway, IFN-γ 
signalling and the p53 pathway feedback loops, none of which 
have an obvious connection to innate immune signalling. How-
ever, miR-155-5p targets also appear to be over-representative of 
the JAK/STAT signalling pathway (PIAS1, PIAS2 and SOCS1) 
and the p38 MAP kinase pathway (MEF2A, TAB2, MAP3K7, 
MAP3K10 and RPS6KAS). Interestingly, the TLR signalling 
pathway was over-represented in the list of potential miR-155-3p 
targets (MDM4, TEP1, MAPK13, MAPK14).
The unusually large response of miR-155-3p, along with the 
interesting kinetics, lead to a more detailed investigation of the 
finding. Changes to the abundance of pri-miR-155 following 
exposure of macrophages to LPS were monitored alongside 
miR-155-5p and miR-155-3p in 10 human donors, taking a more 
detailed look at either early or later timepoints following stimula-
tion (compiled data, Figure 1H). Unfortunately it was not possible 
to selectively quantify the pre-miR-155 stem-loop precur-
sor. However it is worth noting that previous studies deter-
mined that quantitation of pri-miR-155 and pre-miR-155 gives 
comparable results in leukocytes33,34. Here, miR-155-3p induction 
was found to be remarkably rapid, being detected 20 mins after 
LPS exposure. This seems to correlate with a small ‘dip’ in the 
levels of pri-miR-155. Subsequently both miR-155-3p and pri-
miR-155 induction is remarkably similar, peaking at 2–4 hours 
and returning to close to resting levels at 24 hours. In stark con-
trast, miR-155-5p expression rises steadily and continues to rise 
even as pri-miR-155 levels begin to subside.
These data may suggest that different molecular controls may 
govern the abundance of miR-155-5p and miR-155-3p independ-
ently since their expression correlates poorly. In order to examine 
the signalling pathways that might be involved in pri-miR-
155, miR-155-5p and miR-155-3p induction, small molecule 
inhibitors of p38, ERK, JNK and the NF-kB pathway were used 
(Figure 2A–D) to inhibit LPS-dependent induction. All the inhibi-
tors reduced TNF secretion to different extents, as expected 
(Figure 2B). The 4-hour timepoint was chosen as a suitable time 
at which upregulation of both miR-155-5p and miR-155-3p would 
be detectable. However, it should be noted that this is somewhat 
early in the miR-155-5p response (which continues to increase 
at least to 24hrs (for instance, Figure 1G and 35). Moreover, 
it is slightly late in the TNF mRNA response, which peaks at 
~1 hr (Figure 3A). This is likely the explanation for the limited 
effect of p38 and ERK inhibition on TNF mRNA transcription 
at 4hrs, which could be observed at 1 hr (raw data file 11_005, 
available on OSF29).
Reduction in LPS-dependent induction of pri-miR-155, miR-
155-5p and miR-155-3p by IL-10 was confirmed in these experi-
ments (Figure 2A), in agreement with previous literature8,33. 
However, neither the p38 inhibitor SB203580 nor the ERK inhibi-
tor PD98059 significantly influenced induction at 4 hrs. The JNK 
inhibitor SP600125 decreased expression of all three molecules 
similarly by around 50%; however, by far the most profound 
decrease was with PSI, which decreased pri-miR-155 and miR-
155-5p levels about 5-fold, but miR-155-3p levels about 16-fold, 
a statistically significant difference. In addition, the transla-
tion inhibitor cycloheximide was used to investigate whether 
pri-miR-155 was induced following a primary or secondary 
response in MDMs. pri-miR-155 was super-induced by cyclohex-
imide, similarly to TNF mRNA in these cells (a well-recognised 
phenomenon, Figure 2B). However, neither miR-155-3p nor 
miR-155-5p was significantly changed in these circumstances 
(Figure 2A). This data suggests that different pathways may exist 
that control the abundance of pri-miR-155 compared to either of 
the mature miR-155 miRNAs, however additional experiments 
would be required to propose a model.
The M. ulcerans exotoxin mycolactone is known to be immu-
nosuppressive and strongly inhibit the production of cytokines, 
including TNF, from monocytes and macrophages36 due to 
blockade of Sec61-dependent translocation of proteins into the 
endoplasmic reticulum25. In order to determine whether LPS-
dependent induction of miR-155 was a primary or secondary effect 
due to alteration of cytokine production, we investigated whether 
it altered the expression of miR-155 isoforms (Figure 2C, D). 
Mycolactone (either purified from the bacteria or chemically 
synthesised) strongly blocked the production of TNF, whilst hav-
ing a minimal effect on TNF mRNA abundance (Figure 2D), 
as expected23. These experiments only revealed small fluctua-
tions in pri-miR-155, miR-155-5p and miR-155-3p (Figure 2C) 
ruling out secondary pathways.
pri-miR-155, miR-155-5p and miR-155-3p are differentially 
induced following stimulation by a wide range of 
proinflammatory cytokines, TLR ligands, and in other 
primary myeloid cells
In order to examine whether the differential regulation of the 
two strands of miR-155 derived from pri-miR-155 was unique 
to LPS (TLR4) stimulation of MDM, a wide variety of differ-
ent TLR ligands were tested over a timecourse in a single human 
donor. While further repetition would be need to make firmer con-
clusions, this data suggested that IL-1β, TNF, Pam3Cys (TLR1/2), 
MALP-2 (TLR2/6), Flagellin (TLR5) and R848 (TLR7/8) are 
all able induce a broadly equivalent upregulation of steady 
state pri-miR-155 abundance over the 4hr timecourse of the experi-
ment (Figure 3A). On the other hand, the TLR3 ligand poly(I:
C) only induced a very weak response by pri-miR-155 despite 
a robust induction of IP-10 cytokine secretion (downstream of 
type I interferons, Figure 3B).
Page 9 of 31
Wellcome Open Research 2019, 4:43 Last updated: 12 FEB 2020
Figure  3.  Differential  regulation  of miR-155-5p  and miR-155-3p  by  other TLR  ligands  and  cytokines,  and  in  other myeloid  cells. 
(A, B) Human 1°MDMs were exposed to a range of TLR ligands or cytokines for different time periods and total RNA was extracted and 
cell culture supernatants were collected. Cytokines were IL-1β and TNF, both at 10 ng/ml. TLR ligands were 10 ng/ml LPS (TLR4); 10 ng/ml, 
poly(:IC) (TLR3); 20 µg/ml, Pam3Cys(TLR1/2); 10 ng/ml, MALP-2 (TLR2/6); 30 ng/ml, Flagellin (TLR5); 10 ng/ml and R848 (TLR7/8); 1 µg/ml. 
(C, D) Either primary monocytes or MDMs differentiated with GM-CSF (as opposed to M-CSF) were exposed to LPS for different time 
periods and total RNA was extracted. (A, C) Relative changes to the steady state levels of TNF mRNA and pri-miR-155, miR-155-5p, 
and miR-155-3p over time; the endogenous control for the miRNAs was miR-16-5p, for TNF and pri-miR-155 it was GAPDH. Mean±SD of 
technical triplicates. (B, D) Cytokines in supernatants were quantified by ELISA. In D the left panel is monocytes, and the right panel 
macrophages differentiated with GM-CSF.
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Furthermore, the response was not limited to MDMs that had 
been in vitro differentiated with M-CSF. Primary monocytes, as 
well as MDMs differentiated with GM-CSF, also induced pri-
miR-155, although the response from GM-CSF MDMs was lower 
(Figure 3C) despite a stronger induction of TNF (Figure 3D). 
In all cases, perhaps with the exception of poly(I:C), the upregu-
lation of miR-155-3p was more rapid and of a far larger degree 
than miR-155-5p (Figure 3). In no cases did upregulation of 
miR-155-3p outstrip that of pri-miR-155.
Absolute quantitation of miRNAs using synthetic miR-16-5p, 
miR-155-5p and miR-155-3p
In order to better understand the differential regulation of the 
two strands of miR-155, an approach was developed that facili-
tated the absolute quantitation of miRNAs in cells (AQ miRNA, 
Figure 4A). Since very few specific protocols appear to be available 
for such an approach, the methodology has been described in 
detail as a community resource. Examples of the standard curves 
that resulted from the reverse transcription of synthetic miRNAs 
are shown in Figure 4B for miR-155-5p, miR-155-3p, and miR-
16-5p. This approach routinely resulted in standard curves of 
high quality, with r2 > 0.99 in all cases over a large input range 
(Table 2). The ability of these assays to detect miRNAs dif-
fers slightly depending on the miRNA sequence, for instance the 
detection limit for miR-155-5p and miR-155-3p was 0.001 or 
0.0001 fmol, whereas for miR-16-5p it was always 0.0001 fmol. 
There were also variations in the apparent efficiency for the 
combined reverse transcription and PCR reactions, which were 
around 75%, lower than you would expect for qPCR. However, 
it is important to note that for this is not comparable to the typi-
cal PCR efficiency, as it is a two-step assay where the amount 
of input RNA into reverse transcription was varied. In 
Figure  4.  Absolute  quantitation  of  miR-16-5p,  miR-155-5p  and  miR-155-3p  in  primary  human  monocyte  derived  macrophages. 
(A) Schematic showing the approach for absolute quantitation. (B) Examples of standard curves achieved with the method for each of three 
miRNAs: miR-16-5p, miR-155-5p and miR-155-3p. Mean±SD of triplicate values are shown. (C) Human 1°MDMs were exposed to 100ng/ml 
LPS for different time periods. Total RNA was extracted and miRNA abundance was estimated using the absolute quantitation method in 
singleplex. The donor-to-donor variability of miRNA abundance over time, showing the mean and each donor in a different colour. Note that 
the prevalence of each miRNA varies independently.
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circumstances where input RNA amounts are, by defini-
tion, very low (such as RIP, where RNA is barely detectable by 
nanodrop, not shown), such a reduction in efficiency should 
affect the standard and test samples equivalently.
Absolute quantitation of cellular miRNAs reveals the wide 
difference in abundance of miRNAs
The results of the AQ-miRNA analysis method are shown in 
Figure 4C and enumerated in Table 3. This showed that there 
are, on average, ~12,500 copies of miR-16-5p per macrophage 
(depending on the donor, Figures 4C, summarised in Table 3), 
whereas resting cells contain ~1,300 copies of miR-155-5p 
and ~30 copies of miR-155-3p, which rose to an average of 
~750 copies/cell at 2 hrs. Hence there is a 400-fold difference in 
the abundance between miR-16-5p and miR-155-3p in resting 
cells, but a 16-fold difference after activation. The relative 
abundance of miR-155-5p and miR-155-3p using this approach 
was 45-fold in resting cells and 7-fold after 2hrs of LPS 
stimulation.
It seems likely that the variation seen here reflects truly wide 
donor-to-donor variability. Transforming the fmol/80ng readout 
of the AQ-miRNA assay into copies/cell also makes a number of 
assumptions that may contribute to this variation between experi-
ments, such as similar RNA extraction efficiency and cell count-
ing accuracy. However, the prevalence of each miRNA varies 
independently (for example, the donor displayed in red in 
Figure 4C had the highest miR-16-5p, intermediate miR-155-5p 
levels and the lowest miR-155-3p abundance).
Despite its low abundance, miR-155-3p associates with the 
RISC
One explanation for the low numbers of miR-155-3p molecules 
per cell is that they are simply an artefact of the large increase 
in pri-miR-155 and associated processing of pre-miR-155-5p 
into miR-155-5p. Such processing would presumably release the 
passenger strand, which is not incorporated into the RISC, and 
this might be detectable for a short period before it is degraded. 
Alternatively, the pre-miRs may be actively processed to result 
in miR-155-3p loading in the RISC where they have the potential 
to carry out biological functions.
In order to examine this, the incorporation of miRNAs into the 
RISC was estimated by enriching them using RIP and antibodies 
that recognise human Argonaute proteins. Control experiments 
showed that the approach successfully immunoprecipitated the 
proteins (Figure 5A); as previously reported there was some 
cross-reactivity to a non-relevant protein called Radixin30. Using 
this approach, several thousand copies/cell of miR-16-5p were 
associated with the RISC in both unstimulated and stimulated 
cells (Figure 5B). Fewer copies of miR-155-5p were detected 
in this way; several hundred copies/cell in resting cells, which 
increased in stimulated cells (Figure 5B). Note that at this 
timepoint, there had only been a 3-fold increase in total cel-
lular miR-155-5p (donor shown in pale blue in Figure 4C). 
Importantly, although miR-155-3p could not be detected within 
the RISC above background levels in resting cells, following 
LPS stimulation for 2hrs (the peak of miR-155-3p detection in 
cells) it could be recovered with similar efficiency (Figure 5B). 
This was also true when an alternative method for estimating the 
proportion of miRNAs incorporated into the RISC was used 
(Figure 5C).
Technical challenges and limitations of assessing miRNA 
targets in primary human MDM
The primary focus of this study was to attempt to identify 
miRNAs that could regulate the primary immune response. The 
rapid induction of miR-155-3p seemed to potentially in line with 
this hypothesis, considering that the TLR signalling pathway 
was over-represented in Gene Ontology analysis (Figure 1G). A 
7-mer match for miR-155-3p is predicted in the 3’ UTR of the 
human TNF mRNA in the Targetscan database , although this is 
not well conserved amongst mammals. LPS/TLR4-dependent 
signalling in 1°MDMs induces TNF mRNA within 20mins and 
TNF secretion within 1hr. To analyse this further, inhibition 
Table 2. Performance of standards in the 
assay. The mean values obtained from n=7 
standard curves is shown.
miRNA r2 Slope Efficiency (RT&PCR)
miR-16-5p 0.9985 -4.127 75.0%
miR-155-5p* 0.9984 -4.137 75.5%
miR-155-3p* 0.9977 -4.050 77.2%
*On several occasions the lowest standard (0.0001fmol 
synthetic miRNA) did not give amplification above 
background; in such cases this point was not 
considered, increasing the detection limit of the assay 
to 0.001fmol, and the values are calculated from the 
remaining points.
Table 3. Copy-numbers per cell of different miRNAs 
obtained using the absolute quantitation approach. 
Compiled data from n=4–6 human donors is shown. 
*For some donors, this was below the lowest detectable 
standard in the assay.
miRNA Condition
Total copies/cell
Mean ± SEM Range
miR-16-5p
resting 12,496±1,984 5,653–17,029
2hrs LPS 14,306±1,561 9,969-17,048
24hrs LPS 11,880±2,935 6,052–15,406
hsa-miR-
155-5p
resting 1,315±417 448–2,915
2hrs LPS 5,578±1,361 1,609-7,777
24hrs LPS 9,203±4,216 3,820–17,517
hsa-miR-
155-3p
resting 29±11 1.6*–67
2hrs LPS 767±137 446–1,134
24hrs LPS 35±29 3*–94
*For some donors, this was below the lowest detectable standard in 
the assay.
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Figure 5. miR-16-5p, miR-155-5p and miR-155-3p may all be loaded into the RISC in primary human monocyte derived macrophages. 
(A–C) The RISC complex in human 1°MDM was immunoprecipitated using antibodies that recognise Argonaute proteins (2A8) or control 
sera (ctrl). All data is representative of n=3 independent donors. (A) Western blot analysis of input protein (left panel) or eluted protein (right 
panel). Note that the antibodies cross-react with a protein called Radixin (*). (B) miRNAs loaded into the RISC were isolated by RIP using 2A8 
and control antibodies. RNA isolated from the RISC were subject to absolute quantitation. Mean±SD of triplicate values. (C) miRNAs loaded 
into the RISC were isolated by RIP using 2A8 and control antibodies. RNA isolated from the RISC were quantified as a proportion of those in 
the input. Mean±SD of duplicate values. #: both the input and RIP samples for miR-155-3p had Ct values of 35-36, at the detection limit of 
the PCR.
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of miRNAs was achieved using LNA knockdown oligonucle-
otides that form stable duplexes with both miR-155-5p and 
miR-155-3p (Figure 6). A timepoint of 2 hrs was chosen for 
this experiment, taking into account the kinetics of the different 
induced mRNAs being studied; hence, at 2 hrs induction of TNF 
mRNA, pri-miR-155 and miR-155-3p are all near their peak and 
miR-155-5p induction can be detected. A significant chal-
lenge here was that the liposomes used for transfection have 
profound effects on the signalling pathways within cells even 
in the absence of exogenous DNA. For instance, unstimulated 
1°MDMs that had been exposed to liposomes in serum-free 
medium (but not serum-free medium alone) showed increases in 
TNF mRNA and/or pri-miR-155 (Figure 6A), without the produc-
tion of TNF protein into the media (Figure 6B). This may be due to 
activation of a type I interferon response since, in the two donors 
studied, IFIT1 expression was also upregulated by liposomes 
(Figure 6A). In 1°MDMs that were subsequently stimulated 
with LPS, these differences were less profound (Figure 6D), 
and so while this meant it is not technically meaningful to 
report the effect of inhibition on fold induction of effectors, it 
is possible to report some outcomes of this experiment with 
reasonable confidence, by examining only the data from LPS-
stimulated cells, and using the liposome-treated cells as the 
control/comparator group.
Good dose-dependent knockdown of both miRNAs was achieved 
by this method (Figure 6C), with the maximum effect seen at 
a 200 nM oligonucleotide concentration. However, no effect 
of inhibiting the function of either miRNA could be seen on 
the production of TNF into cell culture supernatants or on 
TNF mRNA.
Raw data for all experiments are available
Discussion
This study investigated changes to miRNA abundance in the 
primary response of human 1°MDMs to LPS. The time peri-
ods chose were deliberately short in order to focus on pri-
mary rather than secondary effects; for instance the plethora of 
cytokines induced by activation of this inflammatory pathway 
also have potent cellular effects themselves. A key finding is that 
very few miRNAs are dynamically regulated within this time 
frame. No miRNAs decreased in abundance in any of the condi-
tions tested, and IL-10 alone had no discernible effect on miRNA 
expression. Only five out of 197 expressed miRNAs showed a 
>1.5-fold change at any time point. Since it is now thought that 
both hsa-miR-886-5p and hsa-miR-886-3p are fragments of 
Vault RNA37, rather than true miRNAs (and have subsequently 
been withdrawn from miRbase), the number may be even lower.
The most dynamically regulated miRNA in this study was 
miR-155-3p, the partner strand of miR-155-5p within highly 
conserved microRNA, miR-155. It is undoubted that miR-155 
(MIR155HG/BIC) and miR-155-5p have important roles in the 
immune response, including both the innate and adaptive arms 
(extensively reviewed in 8). In summary, using genetic knockout 
mice lacking BIC, miR-155 has been shown to be indispensable 
for the B cell maturation, migration, interaction with T cells and 
antibody production8. Furthermore, it has been shown to regu-
late T cell differentiation including promoting Th1, Th17 and 
Tfh development while limiting Th2. Finally, miR-155 is 
required for the development of Tregs and antiviral CD8 T cell 
responses. 
Focussing on the innate immune functions of miR-155, it is 
well-established that pri-miR-155 and miR-155-5p are induced 
by pro-inflammatory stimuli and that this can be regulated by 
negative regulators such as IL-10, TGF-β, glucocorticoids and 
Resolvin D18,33,35,38–41. Direct cellular targets for miR-155-5p 
reported in monocytes, macrophages and dendritic cells include 
SHIP1 [INPP5D; a phosphatase that hydrolyses the 5’ phosphate 
from phosphatidylinositol (3,4,5)-trisphosphate and inositol-
1,3,4,5-tetrakisphosphate and hence acts as a negative regulator 
of TLR/PI3/Akt kinase pathway signalling] and SOCS1 (a nega-
tive regulator of cytokine and TLR-mediated immune responses). 
In macrophages, other direct targets include SMAD2 (part of 
the TGFβ signalling cascade), BCL6 (a transcription fac-
tor that negatively regulates NFκB signalling in macrophages) 
and LXRα [NR1H3, a nuclear receptor family transcription fac-
tor that inhibits inflammatory responses in macrophages and pro-
motes anti-inflammatory markers such as Arginase 1 (ARG1)]8. 
These targets are unified by promoting regulatory or negative 
effects on inflammatory signalling, and hence inhibition of 
miR-155-5p induction (either by genetic knockout or knock-
down) has been reported to enhance TNF secretion in response 
to LPS21,22. In addition to an indirect effect, via the direct targets 
listed above, miR-155-5p was reported to directly stablise the 
TNF mRNA22. However, these studies measured TNF responses 
at later timepoints after LPS stimulation than the current report 
(2hrs vs. 18–24hrs in other studies), suggesting that miR-155-5p 
has a greater impact later in the response when its expression 
has increased further and/or secondary responses have had time 
to develop. In addition, some studies used cells that had a com-
plete knockout of miR-155, hence may have a fundamentally dif-
ferent phenotype to wild type primary cells where the miRNA 
function is blocked.
Fewer studies have examined the role of miR-155-3p, never- 
the-less a functional role for miR-155-3p is supported by studies 
in which cellular targets have been described. In plasmacy-
toid dendritic cells and trophoblasts it is a pro-inflammatory, 
augmenting type I interferon expression by suppressing 
IRAK-M (IRAK3) early after TLR7 activation of the cells11,13. 
IRAK-M is a negative regulator of TLR signalling via Myd88 
whose expression is restricted to myeloid cells42, including the 
macrophages that were the focus of the current work. By restrict-
ing its expression transiently during the cell activation process 
via miR-155-3p, the inflammatory burst from the cells would 
be enhanced for a limited period, although this was not directly 
studied. Other reported targets include NKIRAS and PTEN in 
trophoblasts13, two Hsp40 genes (Dnaja2 and Dnajb1) controlling 
murine Th17 differentiation16, MEF2C during cardiogenesis from 
embryonic stem cells17, CREBRF during the hypoxia-induced 
IL-6 response in glioblastoma18, and lymphotoxin-beta (LT-β) 
a positive regulator of non-canonical NF-kB signalling in MCL 
where it has tumour suppressing properties19.
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Figure 6. No effect of miR-155-5p or miR-155-3p inhibition on the production of TNF by primary human MDMs. Human 1°MDMs were 
transfected with miRcury LNA miRNA knockdown probes (either the negative control Scramble-miR, scr, or miR-155-5p or miR-155-3p) using 
Dharmafect 1. Duplicate 2 hr transfections were performed and one set of cells were stimulated with LPS for 2 hrs, while the unstimulated 
rested for an additional 2 hrs. Supernatants were collected for the measurement of secreted cytokines and total RNA was extracted. 
(A) Abundance of TNF and IFIT1 mRNA and pri-miR-155 by fold-change in unstimulated control cells, compared to cells alone stimulated 
with LPS (comparator; GAPDH). Each dot is the mean of technical triplicates from qPCR. (B) TNF secretion from unstimulated control 
cells, compared to cells alone stimulated with 100 ng/ml LPS. Each dot is the mean of technical duplicate from ELISA. (C) Efficiency 
of “knockdown” was assessed by relative abundance of miRNAs in LPs-stimulated cells (comparator; miR-16-5p). Mean±SEM, n=2–4. 
(D) Relative abundance of TNF mRNA and secreted protein in the LPS-stimulated cells. Mean±SEM, n=2–4.
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While most of these targets of miR-155-5p and miR-155-3p are 
listed in databases of predicted targets such as miRDB and Tar-
getscan, only SOCS1 appeared in a statistically over-represented 
pathway in Gene Ontology analysis suggesting that such 
an approach might miss biologically relevant targets. TNF is 
listed as a predicted direct target of miR-155-3p, albeit poorly-
conserved amongst mammals. However, TNF secretion was not 
affected by miR-155-3p inhibition even when examined at peak 
induction. No other functional analysis was performed in the 
current study.
The differences in relative induction demonstrated for 
miR-155-5p and miR-155-3p in LPS/TLR4-stimulated mac-
rophages is in line with a previous report that studied the TLR7 
(R837, also known as Imiquimod) response in plasmacytoid den-
dritic cells, with similar kinetic and amplitude characteristics11. 
These authors proposed a model whereby the differential regula-
tion of the miRNAs was ascribed to KH-type splicing regulatory 
protein (KHSRP), which promoted miR-155-5p maturation but 
inhibited miR-155-3p production11. Further work is needed to 
determine whether the same KHSRP-dependent mechanism also 
controls isomer abundance in the LPS response in macrophages, 
but this is likely since the NFκB pathway is activity by both TLR4 
and TLR7/8. Furthermore, other have also shown that KHSRP 
binds to the terminal loop of miR-155 and enhances matura-
tion of miR-155-5p during the LPS response in murine bone 
marrow-derived macrophages, although miR-155-3p was not 
quantified in this study43.
Other mechanisms might also explain the phenotype observed, 
such as changes to the stability and/or degradation rates of the dif-
ferent isoforms during the TLR response. Recently, miR-155-5p 
was shown to have a half-life of 10.5hrs, considered to be 
“fast” decaying miRNA44, although it is not yet known how 
TLR-dependent stimulation alters these dynamics. Measuring 
the precursor pre-miR-155 levels during the response using an 
approach that would not also detect pri-miR-155 is consid-
ered essential to the future studies but was not done here, or in 
previous investigations11,43.
Such regulation of the two mature miRs that can derive from 
the single pre-miR, so-called “arm switching/selection”4 is of 
increasingly intense research study. For instance, in a long time-
course study of IFNγ activation of melanoma cells, 4 of the 10 
highest regulated miRNAs were ‘star’ strands (miR-424-3p, 
miR-29b-1-5p, miR-27a-5p and miR23a-5p; current miRbase 
annotations), that were induced where the partner strands were 
not45. Arm selection in miR-193a46 and miR-32447,48 also play 
important roles in cancer. Molecular mechanisms have remained 
elusive so far, although in at least one case this may be driven 
by temperature. Polta and colleagues identified three miRNAs, 
previously denoted as passenger strands (hsa-miR-92a-1-5, 
hsa-miR-27b-5p, and hsa-miR-1260a), that had altered expres-
sion when the temperature varied between 32–39.5°C, and that 
together regulated the expression of PKCα49.
Experiments with chemical inhibitors of different signalling 
pathways showed that, in line with the findings of others, the 
upregulation of miR-155-5p was reduced by IL-10, as well as 
by inhibition of the JNK/AP1 and NFκB pathways (in the lat-
ter case by inhibiting proteasomal degradation of IκBα with 
PSI)33,35,38–41. This explains the much lower induction of pri-miR-155 
in poly(I:C) treated cells since TLR3 is not functionally linked 
to NFκB activation in human 1°MDMs50, hence the small induc-
tion might be JNK/AP1-dependent. ERK and p38 inhibition had 
no effect, again in line with previous findings35,38. Interestingly, 
the relationship between pri-miR-155 and miR-155-3p abun-
dance was maintained during JNK and IL-10 treatment, but 
lost in the presence of PSI where NFκB activation resulted in a 
greater decrease in mature miRNA-155-3p than the pri-miR-155 
precursor. This discrepancy might be a potential starting point 
for further investigations to establish the underlying mechanism 
of the phenotypes observed. Finally, it is well established that 
CHX causes super-induction of LPS-dependent TNF mRNA51, 
as is the case in the current work. The mechanism is not known; 
however, while it is possible that a similar mechanism oper-
ates for pri-miR-155, there is no evidence to support the need for 
de novo protein synthesis in the production of miR-155-5p52.
Despite miR-155-3p undergoing the greatest change in expres-
sion level of any miRNA in primary human MDMs, the absolute 
levels of this miRNA are very low. In resting cells, the 
abundance of miR-155-3p was close to the detection limit of the 
qPCR assays. For a short, transient period after LPS challenge 
the number of copies/cell of this miRNA become in the same 
order as resting levels of miR-155-5p. Furthermore miR-155-3p 
could be recovered from the RISC at this timepoint, suggesting 
that it may have biological function despite its low abundance. 
The use of the AQ miRNA approach is therefore a vital addition 
to fully understand the biological significance of such data. The 
lower limit for miRNA abundance required for biological activ-
ity is not known, although the Targetscan database defines it as 
1,000 copies/cell. None of the papers reporting functional analy-
sis for miR-155-3p described above provided data on the abso-
lute levels of this miRNA in their particular model. Such data 
would potentially provide fine-tuning of this proposed threshold, 
especially since target validation for miRNAs frequently 
involves over-expressing pre-miRs to non-physiological levels,
In conclusion, this work provides a detailed description of the 
induction of miR-155-3p in human 1°MDMs and other mye-
loid cells by a range of inflammatory stimuli including LPS. At 
the peak of its abundance, miR-155-3p is transiently present 
at close to 1,000 copies/cell, and can be recovered from the 
RISC. Together with the functional analysis done by others, 
this lends weight to the assertion that miR-155-3p might have 
biological function in a restricted range of circumstances where 
it is induced. The limitations of the current study are the absence 
of quantification of the pre-miR-155 precursor, the low abun-
dance and wide range of the miR-155-3p response between indi-
vidual donors, and the lack of functional experiments. Some 
of the limitations are technical, resulting from the speed of the 
miR-155-3p response, the exquisite sensitivity of 1°MDMs to 
PAMPs, apparently including the liposomes used to transfect oli-
gonucleotide inhibitors into the cells. More work needs to be 
done to determine if miR-155-3p has a role in inflammation or the 
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immune response. Future studies of miR-155-3p should include 
absolute quantitation alongside relative quantitation, analysis 
of precursor pre-miR-155 and functional analysis.
Data availability
Underlying data
Microarray data (title: microRNA responses of LPS and IL-10 
stimulated primary human monocyte-derived macrophages over 
a short time-course) are available at GEO: accession number 
GSE125572.
Open Science Framework: Transient up-regulation of miR-155-3p 
by lipopolysaccharide in primary human monocyte-derived 
macrophages results in RISC incorporation but does not alter 
TNF expression. https://doi.org/10.17605/OSF.IO/KUBCX29.
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Extended data
Open Science Framework: Transient up-regulation of miR-155-3p 
by lipopolysaccharide in primary human monocyte-derived 
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expertise to confirm that it is of an acceptable scientific standard.
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© 2019 Bhattacharyya S et al. This is an open access peer review report distributed under the terms of the Creative
, which permits unrestricted use, distribution, and reproduction in any medium, provided theCommons Attribution License
original work is properly cited.
 Avijit Goswami
RNA Biology Research Laboratory, CSIR-Indian Institute of Chemical Biology, Kolkata, India
   Suvendra N. Bhattacharyya
RNA Biology Research Laboratory, CSIR-Indian Institute of Chemical Biology, Kolkata, India
We have gone through the changes introduced and are happy to approve it.
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Regulation of miRNA activity in mammalian cells.
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 Reviewer Expertise: Regulation of miRNA activity in mammalian cells.
We confirm that we have read this submission and believe that we have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
 10 October 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16915.r36638
© 2019 Michlewski G. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
   Gracjan  Michlewski
 Division of Infection and Pathway Medicine, University of Edinburgh, Edinburgh, UK
 Zhejiang University - University of Edinburgh Institute, Haining, China
I am convinced by the response to my original review. Moreover, authors did a good job of by toning down
their statements as well as citing appropriate literature.
I am unconvinced that it is not be possible to distinguish pro-miR-155 from pre-miR-155. One simple
solution (which we routinely use in the lab) is to resolve total RNA on a desaturating gel, cut out the
fraction corresponding to the 50-100nt long pre-miRNA and quantify with standard SYBR green
approach. Finally, pri-miR-155 can be easily distinguished from pre-miR-155 by using primers that lie
outside of the pre-miR-155 sequence.
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: microRNA biogenesis, RNA-binding proteins, innate immunity.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 10 Oct 2019
, University of Surrey, Guildford, UKRachel Simmonds
Many thanks for taking the time to review the revised version of the manuscript.
On a technical note, the papers that I referred to in my previous comments where pri-miRNA and
pre-miRNA levels were both measured, these did not perform any additional enrichment for small
RNAs but used total RNA. Indeed, your method would provide the necessary discrimination. 
 No competing interests were disclosed.Competing Interests:
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© 2019 Bhattacharyya S et al. This is an open access peer review report distributed under the terms of the Creative
, which permits unrestricted use, distribution, and reproduction in any medium, provided theCommons Attribution License
original work is properly cited.
 Avijit Goswami
RNA Biology Research Laboratory, CSIR-Indian Institute of Chemical Biology, Kolkata, India
   Suvendra N. Bhattacharyya
RNA Biology Research Laboratory, CSIR-Indian Institute of Chemical Biology, Kolkata, India
In this communication “Transient up-regulation of miR-155-3p by lipopolysaccharide in primary human
monocyte-derived macrophages results in RISC incorporation but does not alter TNF expression”, the
author tried to identify an unconventional miR-155-3p to be transiently upregulated during early hours of
LPS stimulation in primary monocyte derived macrophages. The author reported only 5 miRNAs that
happens to be upregulated during initial LPS treatment. It is quite commendable to observe the intent of
the author to quantify the absolute number of miRNA copies/ cell. miR-155-5p and miR-146a are the two
very well-studied miRNAs that has been investigated in context to immune response. The role of
miR-155-3p is yet to be substantiated along with identification of its targets. Some issues regarding this
study have been discussed below.
miR-155-5p is the predominant strand that has been shown to have a copy number of around
1315±417 in resting phase and 9203±4216 during 24 hours of LPS stimulation. Copy number of
miR-155-3p was shown for resting, 2 hours and 24 hours of LPS stimulation. Strangely, the author
missed out mentioning the copy number of miR-155-5p at 2 hours of LPS treatment. Absolute
quantification of miR-155-5p at 2 hours of LPS treated must be provided to comment on
miR-155-3p as “most strongly upregulated miRNA at any timepoint”.
The author mentioned with reference from TargetScan Database miR-155-3p is designated as “not
so confidently identified miRNA” due to its relatively low abundance of about 1000 copies/cell to be
considered biologically functional. The author reported an average 750 copies of miR-155-3p per
cell (which the author also considers as an issue). Can this be considered biologically functional?
Even if there is a 400 fold increase in the number, it still doesn’t qualify for the 1000 copy cut off.
miR-155-5p has a profound effect having previously validated targets, can miR-155-3p shadow the
effect of miR-155-5p?
Processing of pre-miR-155 and half-life of miR-155-3p could be another possible reason for
increased number of miR-155-3p, the author should check the precursor level.
Even if there is RISC incorporation of miR-155-3p, the copy number is almost 100-times less than
miR-155-5p.
Overall, although the idea is interesting, the abundance of miR-155-3p is a real concern.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
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 Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Regulation of miRNA activity in mammalian cells.
We confirm that we have read this submission and believe that we have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however we have significant
reservations, as outlined above.
Author Response 06 Sep 2019
, University of Surrey, Guildford, UKRachel Simmonds
Thank you for taking the time to review my manuscript. As mentioned in the introduction, it reports 
 (several years past). While I agree that the additional experiments suggested wouldhistorical data
give greater insight to the data, there is no prospect of performing them as the lab where the work
was done no longer exists (please see the acknowledgements). Hence this submission to WOR,
whose unique approach of seeking to publish “results worth sharing” rather than complete stories
has given a route to release the data and methodology within, that otherwise would have remained
unpublished. 
I have therefore modified the text to reflect your concerns and the additional/alternative
approaches suggested, and have looked closely at the manuscript overall to ensure that the
conclusions are not overstated on the basis of the available data.
 
miR-155-5p is the predominant strand that has been shown to have a copy number of around
1315±417 in resting phase and 9203±4216 during 24 hours of LPS stimulation. Copy number of
miR-155-3p was shown for resting, 2 hours and 24 hours of LPS stimulation. Strangely, the author
missed out mentioning the copy number of miR-155-5p at 2 hours of LPS treatment. Absolute
quantification of miR-155-5p at 2 hours of LPS treated must be provided to comment on
miR-155-3p as “most strongly upregulated miRNA at any timepoint”.
This data is represented in Figure 4C, but I agree that only showing the 2 hours data for
miR-155-3p in Table 3 was an omission. This has now been corrected.
The author mentioned with reference from TargetScan Database miR-155-3p is designated as “not
so confidently identified miRNA” due to its relatively low abundance of about 1000 copies/cell to be
considered biologically functional. The author reported an average 750 copies of miR-155-3p per
cell (which the author also considers as an issue). Can this be considered biologically functional?
Even if there is a 400 fold increase in the number, it still doesn’t qualify for the 1000 copy cut off.
miR-155-5p has a profound effect having previously validated targets, can miR-155-3p shadow the
effect of miR-155-5p?
Indeed, I complete agree with both these important points. Others have proposed and published
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 Indeed, I complete agree with both these important points. Others have proposed and published
functional roles for miR-155-3p based upon relative expression and without performing absolute
quantification (sometimes based upon massive over-expression of miRNA by transfecting in
miRNA mimics that would be present at far higher levels than upon cellular stimulation). Moreover,
this quantification places miR-155-3p at the limit of biological function under only a time limited
circumstance, albeit that the miRNA can be found within the RISC, and therefore potential of
binding to and regulating targets. The new paragraph at the end of the discussion is intended to
bring these issues out more clearly.
Processing of pre-miR-155 and half-life of miR-155-3p could be another possible reason for
increased number of miR-155-3p, the author should check the precursor level.
I agree that analysing the abundance of the pre-miR-155 hairpin would be ideal, and I have looked
again to see if this would be possible and concluded the following:
No commercial suppliers make a validated assay for pre-miR-155
Previous papers (eg O’Connell PNAS 2007) find that pre-miR-155 is barely detectable at
any timepoint before or during LPS stimulation of BMDM by Northern blot
Very few papers report quantifying pre-miR-155, and in call cases they use in-house
SYBR-based PCR that cannot technically discriminate between pre-miR-155 and
pri-miR-155 (PCR of the stemloop sequence would amplify both the pre-miR and pri-miR)
In those papers that do directly compare pri-miR and pre-miR abundance for miR-155, they
show that the assays give broadly comparable results (not surprising given the above)
Other studies of miR-155-5p and -3p biogenesis (eg Zhou et al, Blood 2010, Ruggiero et al
FEBS Lett 2019) also use pri-miR-155 assays to quantify the precursors, as I did.
 Given that it is not possible to generate further samples for alternate approaches such as Northern
blotting, I have made modifications to the results and discussion in light of the above. Furthermore,
taking the approach of Zhou et al I have relabelled “BIC” as “pri-miR-155” in all figures and text, to
clearly indicate the precursors that have been quantified.  
Examining the half-life of miR-155-3p would also have been an interesting experiment, especially
since miR-155-5p was recently shown to have a half-life of 10.5hrs (Marzi et al, Genome Res 2016
p554). Such notions of miRNA degradation and stability are only recently emerging and tackling
this issue is out of the scope of the current manuscript. However, a discussion of this alternative
explanation of the data is now given in the results and discussion.
As mentioned above, setting up additional experiments is not possible, hence the release of this
 data via Wellcome Open Research rather than a conventional publishing platform.
 No competing interests were disclosed.Competing Interests:
 08 May 2019Reviewer Report
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© 2019 Imig J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work isLicense
properly cited.
 Jochen Imig
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 Jochen Imig
Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
The author uses an outdated microarray technology to characterize the miRNAs involved in primary
immune responses to LPS in human monocyte derived macrophages (MDMs). Only a surprisingly small
fraction of actively expressed miRNAs (5 of 197 out of a total 719 on the array) were induced at least 1.5
fold, with miR-155-3p being the strongest one. This stands in contrast to previous reports that the other
dominant strand (5p) provided the biologically relevant miRNA. The bulk of the manuscript relies on in
simulations followed by time course analysis of relative and absolute expression of different readoutsvitro 
such as TNF, the BIC locus or the two miR-155 strands (5p and 3p). Although suppression of miR-155
had no effect on TNF levels, the author suggests that differential arm selection could play an important
role in controlling immune responses. Lacking functional experiments, as well as no data to propose a
mechanistic model, the author proposes a method for absolute quantification of miRNAs using oligo
templates to generate a standard curve. Using this method, it is shown that A) absolute quantification of
specific miRNAs is feasible and B) miR-155-5p levels exceed miR-155-3p by approximately an order of
magnitude. The author should address a few points, as follows:
The microarray data should be validated with an orthogonal approach, such as a panel of selected
miRNA (up- down-regulated and unchanged) by Taq-Man qRT-PCR or miRNA-Seq of at least 3
healthy individual donors to show the technical validity and reliability of the miRNA expression and
candidate selection thereof.
No functional readouts are included for any of the experiments (for example, phagocytic activity or
M1/M2 polarization) upon miR-155-3p OE or knockdown.
Although it is claimed that miR-155 is one of the most well-known miRNA involved in immune
responses, the data in the paper suggests that at least in MDM, it does not play an important role in
TNF secretion. This point needs further clarification. 
Specific changes
 - Paragraph 2Introduction
Should read "BIC knockout causes defects in germinal center formation and Ig class switching, leading to
immunodeficiency".
 
Methods
Inhibition of miRNAs
Last sentence needs rephrasing or clarification "since pilot experiments showed that extending the
recovery time to significantly reduced the efficiency of inhibition below a meaningful level."
 
Results
Figure 2C) Unclear why the author uses a crude extract of the toxin, when results from a pure synthetic
version are already presented.
Figure 3C) This figure should read "Primary monocytes" instead of "Primary monocytes". It is also unclear
why the author chooses a different cytokine for MDM production.
 
Discussion
Being a sole author, it is understandable that there are physical limitations to the number of assays that
can be performed on primary cells. But this is an obvious condition, making it unnecessary to reiterate it in
the discussion section. The connection between miR-155 and immune activation in the model system
used still remains unclear and needs further literature to support a model.
Is the work clearly and accurately presented and does it cite the current literature?
Partly
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 Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: RNA Biology, long-non coding RNsA, Systems Biology, miRNAs, Epigenetics
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 06 Sep 2019
, University of Surrey, Guildford, UKRachel Simmonds
Thank you for taking the time to review my manuscript. As mentioned in the introduction, it reports 
 (several years past), and the “outdated” technology current at the time thehistorical data
experiment was performed. This submission to WOR, whose unique approach of seeking to
publish “results worth sharing” rather than complete stories has given a route to release the data
and methodology within, that otherwise would have remained unpublished. 
 
The microarray data should be validated with an orthogonal approach, such as a panel of selected
miRNA (up- down-regulated and unchanged) by Taq-Man qRT-PCR or miRNA-Seq of at least 3
healthy individual donors to show the technical validity and reliability of the miRNA expression and
candidate selection thereof.
The manuscript already included orthogonal validation of two upregulated miRNAs (miR-155-5p
and miR-155-3p). Two other upregulated miRNAs (miR-886-5p and -3p) were also validated but I
prefer not to include this data in the manuscript as miR-886 is no longer in miRbase. No miRNAs
were downregulated so there is no suitable miRNA to select in this instance. 
Two unchanged miRNAs were also validated. First, miR-16-5p which was used as the comparator
for the assays. Second, miR-146a-5p which was below the 1.5-fold cut-off in the microarray;
validation of this unchanged miRNA is now included as Figure 1D. Therefore I believe the technical
validity of the microarray is not in question.
No functional readouts are included for any of the experiments (for example, phagocytic activity or
M1/M2 polarization) upon miR-155-3p OE or knockdown.
Indeed, such experiments were not performed, so this data cannot be provided retrospectively.
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 Indeed, such experiments were not performed, so this data cannot be provided retrospectively.
The work sought to examine the responses to the TLR4 signalling pathway rather than
macrophage polarisation per se, that latter of which is achieved using combinations of
stimuli/cytokines that were not used. TNF secretion was used as a positive control for TLR4
stimulation, and expected condition of the unstimulated cells (ie lacking in TNF secretion). This has
been explained in the final paragraph of the introduction. 
Although it is claimed that miR-155 is one of the most well-known miRNA involved in immune
responses, the data in the paper suggests that at least in MDM, it does not play an important role in
TNF secretion. This point needs further clarification.
TNF secretion is only one aspect of the immune response, as laid out in the introduction other
immune functions of miR-155 are in the adaptive immune system. Others (eg Kurowska-Stolarska
et al PNAS 2011) have shown that miR-155-5p can modulate TNF secretion, however these
authors studied longer timepoints (24hrs) than here. A discrepancy is perhaps not surprising given
that miR-155-5p is much more highly expressed at this later timepoint, however these kinetic
differences are out of the scope of the current manuscript that focussed on the primary response at
early timepoints. This point has been emphasised in a new paragraph in the discussion. 
Introduction - Paragraph 2 Should read "BIC knockout causes defects in germinal center formation
and Ig class switching, leading to immunodeficiency".
Corrected
Methods, Inhibition of miRNAs; Last sentence needs rephrasing or clarification "since pilot
experiments showed that extending the recovery time to significantly reduced the efficiency of
inhibition below a meaningful level."
Rephrased
 
Results
Figure 2C) Unclear why the author uses a crude extract of the toxin, when results from a pure
synthetic version are already presented.
This finding may be of interest to the Buruli ulcer research community, where mycolactone is the
pathogenic determinant of the extensive necrosis and immune suppression in that disease.
Mycolactone purified from bacteria likely includes some natural variation in hydroxylation due to
leakiness of the polyketide synthase machinery. I have therefore retained this data in the revised
version.
Figure 3C) This figure should read "Primary monocytes" instead of "Primary monocytes". 
Typo corrected
Discussion; Being a sole author, it is understandable that there are physical limitations to the
number of assays that can be performed on primary cells. But this is an obvious condition, making
it unnecessary to reiterate it in the discussion section. The connection between miR-155 and
immune activation in the model system used still remains unclear and needs further literature to
support a model.
The discussion now includes a concluding paragraph that places the work in context. As
mentioned above, since the results being reported in the unique format of Wellcome Open
Research do not include functional analysis; therefore I have been careful not to overstate the
findings. Proposing a speculative model that isn’t supported by the current data would fall into this
category. 
 No competing interests were disclosed.Competing Interests:
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© 2019 Michlewski G. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
   Gracjan  Michlewski
 Division of Infection and Pathway Medicine, University of Edinburgh, Edinburgh, UK
 Zhejiang University - University of Edinburgh Institute, Haining, China
RE Simmonds presents a study on the role of LPS on human monocyte-derived macrophages in the
context of regulation of miRNA abundance. The author first analysed relative levels of miRNA during LPS
stimulation by microarray technology. This resulted in identification of several miRNAs that were
upregulated more than 1.5 fold upon LPS treatment. The most upregulated was miR-155-3p, derived from
a pri-miR-155 (B cell integration cluster RNA - BIC). Absolute quantification of miR-155-3p. miR-155-5p
and BIC showed intricate, time-dependent regulation of their abundance upon LPS stimulation.
Intriguingly, other pathogen-associated molecular patterns also influenced miR-155-3p. miR-155-5p and
BIC abundance but with various profiles. Finally, the author wanted to see if one of the predicted
miR-155-3p target (TNF) was affected by the miR-155-5p or miR-155-3p inhibition. In general, it's an
interesting study that shows fast and substantial response from the miRNAs to LPS stimulation. That said,
few important controls are missing, the research into miRNA biogenesis is not adequately cited, some
figure panels are not referenced in the text and most importantly there are other possible explanations for
the observed phenotypes that have to be considered.
My specific comments are as follow:
Please expand the CD14 and MD2 abbreviations.
It would be good to provide GO term analysis of miR-155-5p and miR-155-3p predicated and
validated targets. This might help to see a broader picture of what these miRNAs regulate in the
context of innate immune response.
"...miR-155-3p was >100-fold induced at 2 hours, after which the levels began to reduce again
(Figure 1D)..." I am pretty sure this is a reference to Figure 1E.
"...following exposure of macrophages to LPS were monitored alongside miR-155-5p and
miR-155-3p in 10 human donors, taking a more detailed look at either early or later timepoints
following stimulation (compiled data, Figure 1E)..." This is a reference to Figure 1F.
The main conclusion of the paper is that the biogenesis of miR-155-5p and miR-155-3p is altered
during LPS stimulation. Unfortunately, there is no evidence for that. One possible way to get this
information would be to perform   pri-miRNA and pre-miRNA processing assays (before andin vitro
after LPS stimulation).
Also, one could analyse the levels of pre-miR-155 upon LPS stimulation. This could add additional
layer of information about which biogenesis step (if any) is regulated.
There is another possible explanation for the observed phenotypes. It is possible that while
miR-155-3p is upregulated in line with the BIC levels, the stability of miR-155-5p is compromised
after LPS stimulation. To assay that, one would have to inhibit pol II (by actinomycin D) and trace
the levels of miR-155-5p and miR-155-3p to calculate their half-life with and without LPS
1
2
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 6.  
7.  
8.  
9.  
10.  
after LPS stimulation. To assay that, one would have to inhibit pol II (by actinomycin D) and trace
the levels of miR-155-5p and miR-155-3p to calculate their half-life with and without LPS
stimulation.
I don't understand the use of cycloheximide? I would rather see inhibition of pol II by actinomycin D
(as described before) to see if the regulation of miR-155 is uncoupled from the regulation of
transcription.
The reference to Figure 3D is missing.
The references to papers in miRNA biogenesis filed are completely missing. There is a mention of
the KHSRP protein regulating miRNA biogenesis but no reference provided. My advice is to at
least cite some recent comprehensive reviews on this subject (Treiber  . 2019 , Michlewski andet al
Caceres 2019  and Creugny  . 2018 ).et al
The author reports that there were failed attempts to validate predicted mRNA targets for
miR-155-3p function. This is a wrong approach. The focus should be on the proteins that these
mRNAs code as the effects of miR-155-3p could be mostly visible at the level of protein translation.
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 Author Response 06 Sep 2019
, University of Surrey, Guildford, UKRachel Simmonds
Thank you for taking the time to review my manuscript. As mentioned in the introduction, it reports 
 (several years past). While I agree that the additional experiments suggested wouldhistorical data
give greater insight to the data, there is no prospect of performing them as the lab where the work
was done no longer exists (please see the acknowledgements). Hence this submission to WOR,
whose unique approach of seeking to publish “results worth sharing” rather than complete stories
has given a route to release the data and methodology within, that otherwise would have remained
unpublished. 
I have therefore modified the text to reflect your concerns and the additional/alternative
approaches suggested, and have looked closely at the manuscript overall to ensure that the
conclusions are not overstated on the basis of the available data.
My specific comments are as follow:
Please expand the CD14 and MD2 abbreviations.
Expanded as requested
It would be good to provide GO term analysis of miR-155-5p and miR-155-3p predicated and
validated targets. This might help to see a broader picture of what these miRNAs regulate in the
context of innate immune response.
I have performed GO term analysis from miRDB predicted targets for miR-155-5p and miR-155-3p
using the Panther over-representation test and the annotation dataset of Panther pathways. This is
now presented as Figure 1H, and next text describes the pathways relevant to innate immunity. I’m
not convinced that it’s terribly helpful. The recent and extensive review in original reference 6,
Alivernini et al has focussed on the currently known validated targets, and I have included a more
detailed description of the broader picture and cited this reference again at the end of the
discussion. 
"...miR-155-3p was >100-fold induced at 2 hours, after which the levels began to reduce again
(Figure 1D)..." I am pretty sure this is a reference to Figure 1E.
"...following exposure of macrophages to LPS were monitored alongside miR-155-5p and
miR-155-3p in 10 human donors, taking a more detailed look at either early or later timepoints
following stimulation (compiled data, Figure 1E)..." This is a reference to Figure 1F.
My apologies for the mislabelling. This has been corrected, taking into account the addition of
further validation data requested by another reviewer.
The main conclusion of the paper is that the biogenesis of miR-155-5p and miR-155-3p is altered
during LPS stimulation. Unfortunately, there is no evidence for that. One possible way to get this
information would be to perform in vitro pri-miRNA and pre-miRNA processing assays (before and
after LPS stimulation).
I was very careful to avoid making this conclusion, as I agree that further work would be needed to
support such a contention. It is not the conclusion that was stated in the original abstract nor the
discussion. However, in response to your comment I have reworded these to ensure that this
cannot be misunderstood by other readers.
Also, one could analyse the levels of pre-miR-155 upon LPS stimulation. This could add additional
layer of information about which biogenesis step (if any) is regulated.
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 layer of information about which biogenesis step (if any) is regulated.
I agree that analysing the abundance of the pre-miR-155 hairpin would be ideal, and I have looked
again to see if this would be possible and concluded the following:
No commercial suppliers make a validated assay for pre-miR-155
Previous papers (eg O’Connell PNAS 2007) find that pre-miR-155 is barely detectable at
any timepoint before or during LPS stimulation of BMDM by Northern blot
Very few papers report quantifying pre-miR-155, and in call cases they use in-house
SYBR-based PCR that cannot technically discriminate between pre-miR-155 and
pri-miR-155 (PCR of the stemloop sequence would amplify both the pre-miR and pri-miR)
In those papers that do directly compare pri-miR and pre-miR abundance for miR-155, they
show that the assays give broadly comparable results (not surprising given the above)
Other studies of miR-155-5p and -3p biogenesis (eg Zhou et al, Blood 2010, Ruggiero et al
FEBS Lett 2019) also use pri-miR-155 assays to quantify the precursors, as I did.
Given that it is not possible to generate further samples for alternate approaches such as Northern
blotting, I have made modifications to the results and discussion in light of the above. Furthermore,
et altaking the approach of Zhou  I have relabelled “BIC” as “pri-miR-155” in all figures and text, to
clearly indicate the precursors that have been quantified.  
There is another possible explanation for the observed phenotypes. It is possible that while
miR-155-3p is upregulated in line with the BIC levels, the stability of miR-155-5p is compromised
after LPS stimulation. To assay that, one would have to inhibit pol II (by actinomycin D) and trace
the levels of miR-155-5p and miR-155-3p to calculate their half-life with and without LPS
stimulation.
This would indeed be an interesting experiment, complicated by the fact that miR-155-5p itself is
able to stabilise mRNA transcripts such as TNF (see Bala et al JBC 2011 p1436) and that
miR-155-5p was recently shown to have a half-life of 10.5hrs (Marzi et al, Genome Res 2016
p554). Actinomycin D would surely have killed cells after this period of exposure, where such
experiments usually run for a  couple of hours a most. Such notions of miRNA degradation and
stability are only recently emerging and tackling this issue is out of the scope of the current
manuscript. However, a discussion of this alternative explanation of the data is now given in the
results and discussion.
I don't understand the use of cycloheximide? I would rather see inhibition of pol II by actinomycin D
(as described before) to see if the regulation of miR-155 is uncoupled from the regulation of
transcription.
As already mentioned in the text, cycloheximide is a standard test to separate out responses that
required protein synthesis (secondary response) from that that done (primary response). I have
now clarified this in the introduction.
The reference to Figure 3D is missing.
Corrected
The references to papers in miRNA biogenesis filed are completely missing. There is a mention of
the KHSRP protein regulating miRNA biogenesis but no reference provided. My advice is to at
least cite some recent comprehensive reviews on this subject (Treiber et al. 2019, Michlewski and
Caceres 2019 and Creugny et al. 2018).
With respect, one of the references you provide (Creugney et al) was already citied (reference 1). I
have included your review and the other reference as requested.
The author reports that there were failed attempts to validate predicted mRNA targets for
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 The author reports that there were failed attempts to validate predicted mRNA targets for
miR-155-3p function. This is a wrong approach. The focus should be on the proteins that these
mRNAs code as the effects of miR-155-3p could be mostly visible at the level of protein translation.
Indeed, a variety of approaches are possible to achieve this, and several were used. The
advantage of using mRNA rather than protein abundance is that it is possible to screen a larger
number of potential candidates. Since miRNAs regulated both by inhibiting translation and by
causing target mRNAs to be degraded this approach is acceptable. Never-the-less I have re-edited
the discussion section to highlight different areas, and expand on the study limitations in response
 to all reviewer comments and the manuscript no longer refers to these failed attempts.
 No competing interests were disclosed.Competing Interests:
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